Adocia SA (0QAI.L)
| Previous close | 6.12 |
| Open | 5.37 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's range | 5.37 - 5.37 |
| 52-week range | 5.37 - 5.37 |
| Volume | |
| Avg. volume | N/A |
| Market cap | 37.452M |
| Beta (5Y monthly) | 1.23 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -3.35 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Business Wire
ADOCIA Announces First Half 2022 Financial Results and Provides a Business Update
LYON, France, September 19, 2022--Regulatory News: Adocia (Euronext Paris: FR0011184241 – ADOC) (Paris:ADOC), a clinical-stage biopharmaceutical company focused on the research and development of innovative therapeutic solutions for the treatment of diabetes and other metabolic diseases, announces today its financial results for the six months ended June 30th, 2022.
- Business Wire
Adocia Will Release Its 2022 Half-year Results on September 19th and Hold a Webinar on September 20th
LYON, France, September 15, 2022--Regulatory News: Adocia (Euronext Paris: FR0011184241 - ADOC), a clinical-stage biopharmaceutical company focused on the research and development of innovative therapeutic solutions for the treatment of diabetes and other metabolic diseases, will release its first-half 2022 results on September 19th, 2022, post-market close.
- Business Wire
Number of Shares and Voting Rights of ADOCIA as of August 31st, 2022
LYON, France, September 14, 2022--Regulatory News: Pursuant to the provisions of article L. 233-8 II of the French « Code de Commerce » and article 223-16 of the French stock-market authorities (Autorité des Marchés Financiers, or "AMF") charter ADOCIA SA, a French société anonyme (corporation), 115, avenue Lacassagne, 69003 Lyon, (Euronext Paris: FR0011184241 – ADOC) (Paris:ADOC) a clinical stage biopharmaceutical company focused on treatment of diabetes, obesity and metabolic diseases with inn
